Innate Pharma SA
IPHA1.790USD
+0.040+2.29%
Cierre 12/22, 16:00（ET）Cotizaciones retrasadas 15 min
164.96MCap. mercado
PérdidaP/E TTM
Más Datos de Innate Pharma SA Compañía
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Información de Innate Pharma SA
Símbolo de cotizaciónIPHA
Nombre de la empresaInnate Pharma SA
Fecha de salida a bolsaOct 31, 2006
Director ejecutivoDickinson (Jonathan Elliot)
Número de empleados181
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 31
Dirección117 avenue de Luminy
CiudadMARSEILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal13009
Teléfono33430303030
Sitio Webhttps://www.innate-pharma.com/
Símbolo de cotizaciónIPHA
Fecha de salida a bolsaOct 31, 2006
Director ejecutivoDickinson (Jonathan Elliot)
Ejecutivos de Innate Pharma SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Member of the Supervisory Board, Representative of Bpifrance Participations
Member of the Supervisory Board, Representative of Bpifrance Participations
--
--
Ms. Claire De Saint-blanquat
Ms. Claire De Saint-blanquat
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
--
--
Dr. Sally Bennett
Dr. Sally Bennett
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 17 de nov
Actualizado: lun., 17 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.05%
Citadel Advisors LLC
0.02%
Otro
99.86%
Accionistas
Accionistas
Proporción
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.05%
Citadel Advisors LLC
0.02%
Otro
99.86%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
0.07%
Research Firm
0.05%
Hedge Fund
0.02%
Investment Advisor
0.01%
Otro
99.85%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
19
159.42K
0.17%
-86.46K
2025Q2
17
157.41K
0.17%
-54.22K
2025Q1
22
261.37K
0.29%
-22.81K
2024Q4
23
278.64K
0.34%
-188.16K
2024Q3
25
406.53K
0.50%
-579.77K
2024Q2
27
405.72K
0.50%
-529.94K
2024Q1
29
344.92K
0.22%
-517.69K
2023Q4
32
202.70K
0.25%
-1.13M
2023Q3
36
377.53K
0.47%
-1.02M
2023Q2
36
293.58K
0.36%
-1.21M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
AllianceBernstein L.P.
60.75K
0.07%
+36.48K
+150.33%
Jun 30, 2024
Morgan Stanley & Co. International Plc
51.22K
0.06%
+7.70K
+17.69%
Jun 30, 2025
Citadel Advisors LLC
26.62K
0.03%
+2.35K
+9.68%
Jun 30, 2025
UBS Financial Services, Inc.
5.96K
0.01%
-3.04K
-33.82%
Jun 30, 2025
GAMMA Investing LLC
2.28K
0%
-1.18K
-34.00%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
470.00
0%
-205.00
-30.37%
Jun 30, 2025
Barclays Bank PLC
307.00
0%
--
--
Jun 30, 2025
Optiver Holding B.V.
101.00
0%
--
--
Jun 30, 2025
Tower Research Capital LLC
--
0%
-3.00
-100.00%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ActivePassive International Equity ETF
0%
DFA Dimensional Intl Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
Proporción0%
DFA Dimensional Intl Sustainability Core 1 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Innate Pharma SA?
Los cinco principales accionistas de Innate Pharma SA son:
AllianceBernstein L.P. posee 60.75K acciones, lo que representa el 0.07% del total de acciones.
Morgan Stanley & Co. International Plc posee 51.22K acciones, lo que representa el 0.06% del total de acciones.
Citadel Advisors LLC posee 26.62K acciones, lo que representa el 0.03% del total de acciones.
UBS Financial Services, Inc. posee 5.96K acciones, lo que representa el 0.01% del total de acciones.
GAMMA Investing LLC posee 2.28K acciones, lo que representa el 0.00% del total de acciones.
AllianceBernstein L.P. posee 60.75K acciones, lo que representa el 0.07% del total de acciones.
Morgan Stanley & Co. International Plc posee 51.22K acciones, lo que representa el 0.06% del total de acciones.
Citadel Advisors LLC posee 26.62K acciones, lo que representa el 0.03% del total de acciones.
UBS Financial Services, Inc. posee 5.96K acciones, lo que representa el 0.01% del total de acciones.
GAMMA Investing LLC posee 2.28K acciones, lo que representa el 0.00% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Innate Pharma SA?
Los tres principales tipos de accionista de Innate Pharma SA son:
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Citadel Advisors LLC
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Citadel Advisors LLC
¿Cuántas instituciones poseen acciones de Innate Pharma SA (IPHA)?
A fecha de 2025Q3, 19 instituciones poseen acciones de Innate Pharma SA, con un valor de mercado combinado de aproximadamente 159.42K, lo que representa el 0.17% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en 0.00%.
¿Cuál es la mayor fuente de ganancias de Innate Pharma SA?
El --, el segmento empresarial -- generó la ganancia más alta para Innate Pharma SA, ascendiendo a -- y representando el --% de la ganancia total.
